Medicine is changing rapidly. Rather than waiting for illness to appear, we now have tools to understand your individual biology long before symptoms develop. This approach, known as P4 medicine (Predictive, Preventive, Personalised, and Participatory), is reshaping how doctors and patients work together. In Hong Kong, where access to advanced health technology is excellent, biomarkers and genetic tests are opening new possibilities for personalised, preventative care. 

While genetic tests reveal your fixed inherited blueprint, biomarkers tell the story of how your biology is functioning right now. A biomarker is any objectively measured characteristic that reflects a normal biological process, a disease process, or a response to treatment.

The range of biomarkers available today extends far beyond traditional blood tests, and each layer provides different information:

Each of these layers contributes something different: some reflect fixed biology, others change in response to lifestyle, environment, and treatment over time.

Epigenetic clocks estimate your biological age from DNA methylation patterns in your blood. Research shows that a biological age higher than your chronological age is strongly predictive of earlier onset of disease and reduced lifespan. Importantly, epigenetic marks can be modified by lifestyle, making them a measurable feedback tool for the impact of your daily habits.

Discuss with your doctor which tests are evidence-based and actionable for your situation, as the greatest benefit comes when results are matched to your individual biology and health goals in partnership with a clinician you trust.

The future of good health in Hong Kong is not simply about living longer; it is about using the best available science to live better, with care that is as individual as you are.

To help you navigate your health data, the clinical abbreviations are explained below.

1. Hood, L. and Friend, S.H. (2011) 'Predictive, personalized, preventive, participatory (P4) cancer medicine', Nature Reviews Clinical Oncology, 8(3), pp. 184–187. doi:10.1038/nrclinonc.2010.227. Available at: https://www.nature.com/articles/nrclinonc.2010.227 (Accessed: 24 August 2026).
2. Levine, M.E., Lu, A.T., Quach, A., Chen, B.H., Assimes, T.L., Bhatt, S., Hou, L., Baccarelli, A.A., Stewart, J.D., Li, Y., Whitsel, E.A., Wilson, J.G., Reiner, A.P., Aviv, A., Lohman, K., Liu, Y., Ferrucci, L. and Horvath, S. (2018) 'An epigenetic biomarker of aging for lifespan and healthspan', Aging (Albany NY), 10(4), pp. 573–591. doi:10.18632/aging.101414. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC5940111 (Accessed: 24 August 2026).
3. Nurchis, M.C., Altamura, G., Riccardi, M.T., Radio, F.C., Chillemi, G., Bertini, E.S., Garlasco, J., Tartaglia, M., Dallapiccola, B. and Damiani, G. (2023) 'Whole genome sequencing diagnostic yield for paediatric patients with suspected genetic disorders: systematic review, meta-analysis, and GRADE assessment', Archives of Public Health, 81, p. 93. doi:10.1186/s13690-023-01112-4. Available at: https://archpublichealth.biomedcentral.com/articles/10.1186/s13690-023-01112-4 (Accessed: 24 August 2026).
4. Ewans, L.J., Minoche, A.E., Schofield, D., Shrestha, R., Ohnesorg, T., Dorani, N., Hakeem, N., Impey, K., Gomez-Osorio, I. and Jaffe, A. (2022) 'Whole exome and genome sequencing in Mendelian disorders: a diagnostic and health economic analysis', European Journal of Human Genetics, 30(10), pp. 1121–1131. doi:10.1038/s41431-022-01162-2. Available at: https://www.nature.com/articles/s41431-022-01162-2 (Accessed: 24 August 2026).
5. National Comprehensive Cancer Network (2024) NCCN Clinical Practice Guidelines in Oncology: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic (Version 3.2024). Plymouth Meeting, PA: NCCN. Available at: https://www.nccn.org/guidelines/guidelines-detail?category=2&id=1545 (Accessed: 24 August 2026).
6. Lee, C.R., Luzum, J.A., Sangkuhl, K., Gammal, R.S., Sabatine, M.S., Stein, C.M., Kisor, D.F., Limdi, N.A., Lee, Y.M., Scott, S.A., Hulot, J.-S., Roden, D.M., Gaedigk, A., Caudle, K.E., Klein, T.E., Johnson, J.A. and Shuldiner, A.R. (2022) 'Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 Update', Clinical Pharmacology & Therapeutics, 112(5), pp. 959–967. doi:10.1002/cpt.2526. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC9287492 (Accessed: 24 August 2026).
7. Corder, E.H., Saunders, A.M., Strittmatter, W.J., Schmechel, D.E., Gaskell, P.C., Small, G.W., Roses, A.D., Haines, J.L. and Pericak-Vance, M.A. (1993) 'Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families', Science, 261(5123), pp. 921–923. doi:10.1126/science.8346443. Available at: https://www.science.org/doi/10.1126/science.8346443 (Accessed: 24 August 2026).
8. Mol, M.O., van der Lee, S.J., Hulsman, M., van Rooij, J.G.J., Haaksma, M.L., Holstege, H., Scheltens, P., Reinders, M.J.T., Louwersheimer, E. and van der Flier, W.M. (2022) 'Mapping the genetic landscape of early-onset Alzheimer's disease', Alzheimer's Research & Therapy, 14, p. 77. doi:10.1186/s13195-022-01018-3. Available at: https://alzres.biomedcentral.com/articles/10.1186/s13195-022-01018-3 (Accessed: 24 August 2026).
9. Hyman, S.L., Levy, S.E. and Myers, S.M.; Council on Children with Disabilities, Section on Developmental and Behavioral Pediatrics (2020) 'Identification, Evaluation, and Management of Children With Autism Spectrum Disorder', Pediatrics, 145(1), p. e20193447. doi:10.1542/peds.2019-3447. Available at: https://publications.aap.org/pediatrics/article/145/1/e20193447/36917 (Accessed: 24 August 2026).
10. Kaufmann, W.E., Kidd, S.A., Andrews, H.F., Budimirovic, D.B., Esler, A., Haas-Givler, B., Stackhouse, T., Riley, C., Peacock, G., Sherman, S.L., Brown, W.T. and Berry-Kravis, E. (2017) 'Autism Spectrum Disorder in Fragile X Syndrome: Cooccurring Conditions and Current Treatment', Pediatrics, 139(Suppl 3), pp. S194–S206. doi:10.1542/peds.2016-1159H. Available at: https://publications.aap.org/pediatrics/article/139/Supplement_3/S194/34155 (Accessed: 24 August 2026).
11. Ferguson, L.R., De Caterina, R., Görman, U., Allayee, H., Kohlmeier, M., Prasad, C., Choi, M.S., Curi, R., de Luis, D.A., Gil, Á., Kang, J.X., Martin, R.L., Milagro, F.I., Nicoletti, C.F., Nonino, C.B., Ordovas, J.M., Parslow, V.R., Portillo, M.P., Santos, J.L., Serhan, C.N., Simopoulos, A.P., Velázquez-Arellano, A., Zulet, M.A. and Martinez, J.A. (2016) 'Guide and Position of the International Society of Nutrigenetics/Nutrigenomics on Personalised Nutrition: Part 1 — Fields of Precision Nutrition', Journal of Nutrigenetics and Nutrigenomics, 9(1), pp. 12–27. doi:10.1159/000445350. Available at: https://karger.com/jnn/article/9/1/12/182050 (Accessed: 24 August 2026).
12. Zmora, N., Suez, J. and Elinav, E. (2019) 'You are what you eat: diet, health and the gut microbiota', Nature Reviews Gastroenterology & Hepatology, 16(1), pp. 35–56. doi:10.1038/s41575-018-0061-2. Available at: https://www.nature.com/articles/s41575-018-0061-2 (Accessed: 24 August 2026).
13. Chambers, E.S., Preston, T., Frost, G. and Morrison, D.J. (2018) 'Role of Gut Microbiota-Generated Short-Chain Fatty Acids in Metabolic and Cardiovascular Health', Current Nutrition Reports, 7(4), pp. 198–206. doi:10.1007/s13668-018-0248-8. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC6244749 (Accessed: 24 August 2026).
14. Arnett, D.K., Blumenthal, R.S., Albert, M.A., Buroker, A.B., Goldberger, Z.D., Hahn, E.J., Himmelfarb, C.D., Khera, A., Lloyd-Jones, D., McEvoy, J.W., Michos, E.D., Miedema, M.D., Muñoz, D., Smith, S.C., Virani, S.S., Williams, K.A., Yeboah, J. and Ziaeian, B. (2019) '2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease', Circulation, 140(11), pp. e596–e646. doi:10.1161/CIR.0000000000000678. Available at: https://www.ahajournals.org/doi/10.1161/cir.0000000000000678 (Accessed: 24 August 2026).
15. Nordestgaard, B.G., Chapman, M.J., Ray, K., Borén, J., Andreotti, F., Watts, G.F., Ginsberg, H., Amarenco, P., Catapano, A., Descamps, O.S., Fisher, E., Kovanen, P.T., Kuivenhoven, J.A., Lesnik, P., Masana, L., Reiner, Z., Taskinen, M.R., Tokgözoglu, L. and Tybjærg-Hansen, A. (2010) 'Lipoprotein(a) as a cardiovascular risk factor: current status', European Heart Journal, 31(23), pp. 2844–2853. doi:10.1093/eurheartj/ehq386. Available at: https://academic.oup.com/eurheartj/article/31/23/2844/2398484 (Accessed: 24 August 2026).
16. Therriault, J., Brum, W.S., Trudel, L., Macedo, A.C., Bitencourt, F.V., Castro Martins-Pfeifer, C., Nakouzi, M., Pola, I., Wong, M., Kac, P.R., Real, A.P., Witherow, C., Karikari, T.K., Moscoso, A., Zimmer, E.R., Schöll, M., Pascoal, T., Benedet, A.L., Ashton, N.J., Schindler, S.E., Zetterberg, H., Blennow, K. and Rosa-Neto, P. (2025) 'Blood phosphorylated tau for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis', The Lancet Neurology, 24(9), pp. 740–752. doi:10.1016/S1474-4422(25)00227-3. Available at: https://www.sciencedirect.com/science/article/pii/S1474442225002273 (Accessed: 24 August 2026).
17. Siravegna, G., Marsoni, S., Siena, S. and Bardelli, A. (2017) 'Integrating liquid biopsies into the management of cancer', Nature Reviews Clinical Oncology, 14(9), pp. 531–548. doi:10.1038/nrclinonc.2017.14. Available at: https://www.nature.com/articles/nrclinonc.2017.14 (Accessed: 24 August 2026).